- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/555 - Interférons [IFN]
Détention brevets de la classe C07K 14/555
Brevets de cette classe: 294
Historique des publications depuis 10 ans
12
|
23
|
21
|
22
|
27
|
18
|
22
|
25
|
28
|
5
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
Proprétaire |
Total
|
Cette classe
|
---|---|---|
Opko Biologics Ltd. | 77 |
13 |
The Regents of the University of California | 19803 |
9 |
Evotec International GmbH | 76 |
8 |
Sanofi | 4008 |
8 |
Superlab Far East Limited | 15 |
7 |
Werewolf Therapeutics, Inc. | 54 |
7 |
Toray Industries, Inc. | 6886 |
6 |
Regeneron Pharmaceuticals, Inc. | 4223 |
6 |
Rutgers, The State University of New Jersey | 1872 |
6 |
Orionis Biosciences Inc. | 95 |
6 |
The Industry & Academic Cooperation in Chungnam National University (IAC) | 448 |
5 |
Novagen Holding Corporation | 25 |
5 |
CytomX Therapeutics, Inc. | 216 |
4 |
Universiteit Gent | 1328 |
4 |
Vib VZW | 860 |
4 |
Akseera Pharma Corp. | 12 |
4 |
The Board of Trustees of the Leland Stanford Junior University | 6347 |
3 |
Alios BioPharma, Inc. | 66 |
3 |
Memed Diagnostics Ltd. | 74 |
3 |
Prosit Sole Biotechnology (Beijing) Co. Ltd | 6 |
3 |
Autres propriétaires | 180 |